

14th October, 2024

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2024

Board Meeting on Wednesday, 23rd October, 2024

Dear Sir / Madam,

Pursuant to Regulation 29 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 23rd October, 2024, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30th September, 2024.

In this regard, we also write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Tuesday, 1st October, 2024 will remain closed till Friday, 25th October, 2024 (both days inclusive).

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com